Neos Therapeutics, Inc.

Neos Therapeutics, Inc. is a pharmaceutical company founded in 2008, with a focus on developing, manufacturing, and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. The company's slogan "We are creating the Specialty Pharmaceutical Company of Tomorrow...Today" reflects its ambition to innovate within the pharmaceutical industry. Neos initially concentrates on treating ADHD and has two other branded product candidates that are XR medications in ODT or oral suspension dosage forms. The company received a significant $25.00M Post-IPO Equity investment on 01 February 2017, indicating investor confidence and potential for growth. This investment is a testament to the promise Neos holds in the pharmaceutical market and its potential for expansion and development. As the company continues to focus on its inventive drug delivery technologies and new product candidates, it will be interesting to see how it progresses and expands its presence in the biotechnology sector. Neos Therapeutics, Inc. is headquartered in the United States, positioning it within a leading hub for pharmaceutical innovation. With its innovative approach and impactful products in the pipeline, Neos has the potential to make a lasting mark within the biotechnology industry. For potential investors and venture capitalists, Neos Therapeutics, Inc. presents an intriguing opportunity to support and engage with a pioneering company in the pharmaceutical space.